Related Experiment Videos
K-RAS mutation in transitional cell carcinoma of urinary bladder
S Ayan1, G Gokce, H Kilicarslan
1Department of Urology, Medical Biology and Genetics and Pathology, Faculty of Medicine, Cumhuriyet University, Sivas, Turkey.
International Urology and Nephrology
|July 3, 2002
Summary
This study investigated K-RAS mutations in bladder cancer, finding them to be frequent. Further research is needed to confirm the role of these K-RAS gene mutations in cancer development and spread.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Transitional cell carcinoma is the most common type of bladder cancer.
- K-RAS mutations have been implicated in various cancers, but their role in bladder cancer requires further investigation.
Purpose of the Study:
- To determine the frequency of K-RAS gene mutations in human bladder transitional cell carcinoma.
- To analyze the types of K-RAS mutations present in bladder tumors.
Main Methods:
- Tissue specimens from bladder tumor patients were collected.
- Genomic DNA was isolated from tumor tissues.
- Polymerase chain reaction-single-strand conformational polymorphism (PCR-SSCP) analysis was performed on the K-RAS gene (exon 2).
Main Results:
- A heterozygous deletion mutation in the K-RAS oncogene (exon 2) was identified in one patient.
- Point or substitution mutations in the K-RAS gene were detected in 4 out of 14 (4/14) bladder cancer patients using PCR-SSCP.
- The overall frequency of K-RAS mutations in this cohort was notable.
Conclusions:
- K-RAS mutations are not rare in human bladder transitional cell carcinoma.
- The specific role of K-RAS mutations in bladder cancer oncogenesis and tumor infiltration warrants further investigation in larger patient cohorts.